

Press Release – Basel, Switzerland, May 15, 2008

InnoMed PredTox Consortium Members Present Preliminary Study Results

Basel, Switzerland, May 15, 2008 – The 20 leading pharmaceutical companies, academic research organizations and technology providers participating in the European InnoMed PredTox project aim to make more informed decisions earlier in preclinical safety evaluation by combining results from molecular profiling (omics) technologies together with the findings from conventional toxicology. For this purpose, the InnoMed PredTox consortium members have been compiling a comprehensive set of preclinical toxicology data, studying two reference compounds and 14 proprietary compounds that had previously failed in clinical development for toxicity reasons.

At the 47th annual meeting of the Society of Toxicology earlier this year, InnoMed PredTox presented joint analyses of the compiled transcriptomics, proteomics and metabolomics profiling data with conventional toxicological endpoints in blood, urine, liver and kidney samples from rats. The results nicely demonstrate the merits of the systematic, integrated approach adopted by the consortium, and pave the way towards new biomarkers, a better mechanistic understanding of individual toxicological responses, and subsequently to more efficient development processes.

Genedata has provided the computational infrastructure for InnoMed PredTox, in particular the software for data management and analysis. Developed as a customization of the Genedata Expressionist[®] database, the PredTox database currently hosts about 1.3 TB of data and represents the central access point for the consortium members. Data analysis services based on the Genedata Expressionist product suite facilitate the comparison of data between sites and across compounds, which proves to be essential for biological interpretation by the InnoMed PredTox toxicology experts.

“I am very happy about the success of the InnoMed PredTox project, as it validates Genedata’s philosophy of supporting the integrated analysis of large sets of different omics technologies and clinical data. With our Genedata Expressionist platform, we provide a scalable system for efficient biomarker discovery,” said Dr. Othmar Pfannes, CEO of Genedata.

Contact:

Genedata AG

Christiane Becker

Public Relations

Phone +41 61 697 7378

Fax +41 61 697 7244

christiane.becker@genedata.com

www.genedata.com

Publications available on www.innomed-predtox.com:

Application Of A Systems Toxicology Approach To Investigate Troglitazone Hepatotoxicity In The Rat

E. Troesken¹; A. Gruhler²; E. Boitier¹; J.-P. Marchandeu¹; K. Arnold³; B. Bidlingmaier¹; A. Brandenburg⁴; M. Kurz¹; A. Pfenninger¹; J. Schnieders¹; I. Stammberger¹; M. Stolte¹; A. Amberg¹

1. Sanofi-Aventis, Hattersheim, Germany.
2. Novo Nordisk A/S, Bagsværd, Denmark.
3. Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
4. Genedata AG, Basel, Switzerland.

Integrated Transcriptomic And Proteomic Evaluation Of Gentamicin Nephrotoxicity In Rats

E. Com¹; E. Boitier¹; J.-P. Marchandeu¹; M. Courcol¹; J.-F. Leonard¹; M. Duchesne²; B. Genet²; S. Schroeder³; M. Wendt⁴; J.-C. Gautier¹

1. Drug Safety Evaluation, sanofi aventis, Vitry sur Seine, France.
2. Biological Sciences, sanofi aventis, Vitry sur Seine, France.
3. Nycomed GmbH, Barsbüttel, Germany.
4. Genedata AG, Basel, Switzerland.

-Omics In Hepatotoxicity Prediction

A. Mally¹

1. Department of Toxicology, University of Wuerzburg, Wuerzburg, Germany.

An Integrated -Omics Approach Towards A Better Understanding Of Drug-Induced Nephrotoxicity And Useful Biomarkers

F. Staedtler¹

1. Biomarker Development, Novartis Pharma AG, Basel, Switzerland.

About Genedata

Genedata specializes in software and professional services for pharmaceuticals, biotech and related life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data; Genedata Screener® for high throughput screening analysis; and Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and subsidiaries in Tokyo (Japan), Munich (Germany), Konstanz (Germany), Boston (USA) and San Francisco (USA). For more information about Genedata, please visit www.genedata.com

About InnoMed PredTox

InnoMed PredTox aims at reducing a key bottleneck in the R&D process, namely the assessment of drug safety before new drugs enter the market. It has secured €8 million of budget over 40 months, partly funded by the European Commission Life Sciences, Genomics and Biotechnology for Health Priority (LSHB-CT-2005-518170). The project is coordinated by the European Federation of Pharmaceutical Industries and Associations (EFPIA), a body representing the research-based pharmaceutical industry and biotech SMEs operating in Europe. The members in the consortium include: Bayer Schering Pharma AG, Boehringer Ingelheim, F. Hoffmann-La Roche, Johnson & Johnson Pharmaceutical R & D, Lilly S.A., Merck KGaA, MerckSerono, Nycomed, Novo Nordisk A/S, DK, Novartis, Organon, Sanofi-Aventis (Germany, France), Servier, the Universities of Dublin, Hacettepe and Würzburg, as well as Bio-Rad and Genedata. For more information please visit www.innomed-predtox.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.